TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01751906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Description: * Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE
Description: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Study: NCT04110951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama Breathing Technique
Description: Yogic Breathing Technique

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation technique
Description: Progressive relaxation technique
Study: NCT04379479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dialyzable Leukocyte Extract
Description: Experimental Intervention. Dialyzable Leukocyte Extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral
Description: Placebo
Study: NCT03827382

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
Study: NCT03470324

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: [standard STN]
Description: standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: [STN+SNr]
Description: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing therapy
Description: Swallowing therapy with speech therapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing therapy
Description: Swallowing therapy with speech therapist
Study: NCT00328562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839 (Iressa)
Study: NCT02307396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulpiride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulpiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bromperidol
Study: NCT04580446

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated intensity modulated radiotherapy
Description: Hypofractionated intensity modulated radiotherapy with concurrent chemotherapy (weekly cisplatin)
Study: NCT02307396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromperidol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zuclopenthixol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioridazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioridazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Study: NCT00328562

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Study: NCT00368381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
Study: NCT01089413

Intervention type: DRUG
Intervention: bevacizumab [Avastin]
Description: As prescribed by physician
Study: NCT04554693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: 250 mg oral three times a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
Study: NCT01050504

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT01480804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention for age specific barriers to self care
Description: The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
Study: NCT03277430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Live donor uterus transplantation
Description: Transplantation of uterus from a living donor.
Study: NCT01050504

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03277430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor uterus transplantation
Description: Transplantation of uterus from a deceased brain-dead donor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
Study: NCT04204265

Intervention type: DEVICE
Group type: OTHER
Intervention: Monovisc
Description: A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
Study: NCT01271010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
Study: NCT04324164

Intervention type: DRUG
Intervention: Third-generation EGFR-TKI
Description: Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

Intervention type: DRUG
Intervention: Third-generation EGFR-TKI
Description: Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

Intervention type: DRUG
Intervention: EGFR-TKI
Description: All EGFR-TKI

Intervention type: DRUG
Intervention: EGFR-TKI
Description: All EGFR-TKI

Intervention type: DRUG
Intervention: EGFR-TKI
Description: All EGFR-TKI

Intervention type: DRUG
Intervention: EGFR-TKI
Description: All EGFR-TKI

Intervention type: DRUG
Intervention: EGFR-TKI
Description: All EGFR-TKI
Study: NCT02637479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaKnife®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT03296371

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo saliva or buccal mucosa collection

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01698905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry.
Study: NCT01427153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthopaedic manual physical therapy
Description: OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroid injection to the tibiofemoral joint
Study: NCT03326713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling & Navigation (TCN)
Description: A health coach will conduct a 30-45 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed Targeted Print (TP)
Description: Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
Study: NCT04082650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 4000IU per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same doses with vitamin D
Study: NCT03750331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ap'Telecare
Description: an internet application on a computer, tablet or smartphone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional schedule
Description: a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule
Study: NCT00235404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent treatment
Description: Specialized care in preparing recharge to home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual recharge directly from hospital to home
Study: NCT01271010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.
Study: NCT02592616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON
Description: No exercise intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CW
Description: One hour of continuous walking on a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW
Description: One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
Study: NCT02258971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR oral
Description: Oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEA 2180 BR infusion
Description: Solution for infusion to be reconstituted with isotonic saline
Study: NCT01576146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
Study: NCT02926027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vascepa
Description: Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01557257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02
Description: Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone block
Description: Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02
Description: Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone block
Description: Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyContin
Description: Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
Study: NCT01625832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent coronary sinus occlusion
Description: Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent coronary sinus occlusion
Description: Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
Study: NCT02563392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine myomectomy with preventive uterine arteries occlusion
Description: laparoscopic uterine myomectomy with preventive uterine arteries occlusion
Study: NCT01340898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SynflorixTM
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SynflorixTM
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SynflorixTM
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/HiberixTM
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/HiberixTM
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/HiberixTM
Description: Intramuscular injection
Study: NCT01335984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring & Telemedicine
Description: The subjects who are assigned in the Telemonitoring \& Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: - The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
Study: NCT03761524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Customized V plate fixation
Description: (CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional miniplates fixation
Description: Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
Study: NCT03165734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice medications
Description: Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
Study: NCT02563392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic uterine myomectomy without preventive uterine arteries occlusion
Description: laparoscopic uterine myomectomy
Study: NCT01707771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass
Description: Active Comparator: Roux-en-Y gastric bypass

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and lifestyle modifications
Description: Active Comparator: diet and lifestyle modifications
Study: NCT00501098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned.
Study: NCT01939743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac suppository plus lidocaine gel

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine gel only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel only
Study: NCT03790488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-4014
Description: Specified dose on specified days
Study: NCT02236832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG recording

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG recording

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG recording

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG recording

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG recording

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological examination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological examination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological examination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological examination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological examination
Study: NCT01685840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomarker-guided care NT-proBNP
Description: Device: NT-proBNP
Study: NCT00224289

Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost 0.005%
Description: Latanoprost 0.005% ophthalmic solution QHS 8 weeks
Study: NCT02307396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone